Lenvakast 10 mg contains Lenvatinib, a multi-targeted tyrosine kinase inhibitor (TKI) that blocks several receptors including VEGFR, FGFR, PDGFR, RET, and KIT. By targeting these pathways, Lenvatinib helps reduce tumor blood supply and inhibit cancer cell proliferation.

🔬 Mechanism of Action

Lenvatinib inhibits vascular endothelial growth factor receptors (VEGFR 1–3) and other growth factor receptors. As a result, it:

• Reduces angiogenesis (formation of new blood vessels)
• Slows tumor growth
• Limits metastatic progression

This multi-pathway inhibition makes it effective in various advanced cancers.

💊 Indications

Lenvakast 10 mg is indicated for:

• Differentiated Thyroid Cancer (DTC) refractory to radioactive iodine therapy
• Hepatocellular Carcinoma (HCC) (unresectable)
• Advanced Renal Cell Carcinoma (RCC) (in combination with other agents)
• Advanced Endometrial Carcinoma (in combination therapy)

📌 Key Features of Lenvakast 10 mg

• Strength: 10 mg and 4 mg
• Dosage Form: Oral capsule
• Therapeutic Class: Multi-targeted Tyrosine Kinase Inhibitor
• Administration: Taken orally once daily, dose based on indication and body weight
• Monitoring: Blood pressure, liver function, thyroid function, and renal function monitoring required

⚕️ Benefits of Lenvatinib

• Broad-spectrum targeted therapy
• Oral administration for patient convenience
• Proven efficacy in multiple advanced cancers
• Helps delay disease progression

⚠️ Precautions

• May cause hypertension, proteinuria, fatigue, diarrhea, and decreased appetite
• Risk of liver dysfunction and renal impairment
• Regular monitoring essential during therapy
• Dose adjustments may be required based on tolerance
• Use strictly under oncologist supervision

Lenvakast 10 mg (Lenvatinib Capsules) provides a modern targeted treatment option for advanced cancers, helping control tumor progression and improve clinical outcomes when administered under specialized medical care.